ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nivolumab

Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.

Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,031 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 2015145 company-led studies, 14 open or runningNext primary completion: Feb 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only12410 open or runningphase 4since Nov 2, 2015Feb 27, 2007Feb 5, 2027phase 2 · NCT06946797
Ono Pharmaceuticalits history only144 open or runningphase 3since Oct 9, 2014Jan 26, 2009Dec 31, 2027phase 2 · NCT04566380
Pfizerits history only20 open or runningphase 2since Oct 7, 2015Oct 7, 2015none ahead
ella-therapeutics-ltdits history only10 open or runningphase 2since Aug 13, 2020Aug 13, 2020none ahead
excellabio-llc10 open or runningphase 2since Oct 20, 2017Oct 20, 2017none ahead
nilogen-oncosystemsits history only10 open or runningearly phase 1since Dec 3, 2017Dec 3, 2017none ahead
rampart-health-l-l-cits history only10 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
USWM CTits history only10 open or runningphase 2since Oct 26, 2022Oct 26, 2022none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of excellabio-llc only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2017First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT03342417 · 5 enrolled · United States

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study excellabio-llc leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03342417Ovarian Neoplasms · United States2TerminatedMay 29, 20195

How it is read

Names in the registry

  • “Nivolumab”, 115 entries
  • “nivolumab”, 18 entries
  • “ONO-4538”, 13 entries
  • “BMS-936558 (MDX-1106)”, 5 entries
  • “Nivolumab + Relatlimab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.